摘要
目的 探讨罗沙替丁联合泮托拉唑治疗重症患者应激性溃疡(SU)的疗效及安全性.方法 收集2022年1至12月接受治疗的SU重症患者病例共205例,随机分为对照组(泮托拉唑钠治疗)101例和观察组(泮托拉唑钠联合罗沙替丁治疗)104例,采用倾向性得分匹配法按照1:1进行匹配,最终分为对照组63例和观察组63例.比较2组临床疗效、机体氧化应激标志物水平、白细胞介素.2(IL-2)水平、白细胞介素.6(IL-6)水平、肿瘤坏死因子.α(TNF-α)水平、急性生理与慢性健康状况(APACHE Ⅱ)评分、序贯器官衰竭(SOFA)评分及感染相关并发症发生情况.结果 观察组总有效率(96.83％)高于对照组(85.71％),差异有统计学意义(P＜0.05).治疗后,2组超氧化物歧化酶(SOD)和IL-2水平均高于治疗前,丙二醛(MDA)、氧自由基(ROS)、IL-6及TNF-α水平,以及APACHE Ⅱ和SOFA评分均低于治疗前(P＜0.05);观察组SOD和IL-2水平高于对照组,MDA、ROS、IL-6及TNF-α水平,以及APACHE Ⅱ、SOFA评分低于对照组,差异有统计学意义(P＜0.05).感染相关并发症总发生率(3.17％)低于对照组(12.70％),差异有统计学意义(P＜0.05).结论 罗沙替丁联合泮托拉唑治疗重症患者SU的疗效优于单用泮托拉唑,既能减轻机体氧化应激和炎症反应,又可以减少感染相关并发症的发生.
Abstract
AIM To explore the efficacy and safety of roxatidine combined with pantoprazole in treating stress ulcers(SU)in critically ill patients.METHODS A total of 205 critically ill patients with SU treated in the hospital from January to December of 2022 were collected for the study and randomly assigned to the control group(101 patients treated with pantoprazole sodium)and observation group(104 patients treated with the combination of pantoprazole sodium and rosuvastatin).Using propensity score matching in a 1:1 ratio,the study ultimately included 63 patients in the control group and 63 patients in the observation group.The clinical efficacy,levels of biomarkers of oxidative stress,interleukin-2(IL-2),interleukin-6(IL-6),and tumor necrosis factor-α(TNF-α)levels,acute physiology and chronic health status(APACHE Ⅱ)score,sequential organ failure(SOFA)score,and incidence of infectious complications were compared between 2 groups.RESULTS The total effective rate of the observation group was 96.83％(61/63),which was higher than that of the control group,85.71％(54/63),with a significant difference(P＜0.05).After treatment,the levels of superoxide dismutase(SOD)and IL-2 in the observation group and control group were higher than prior treatment.Levels of malondialdehyde(MDA),reactive oxygen species(ROS),IL-6,TNF-α,APACHE Ⅱ,and SOFA scores were lower than prior treatment(P＜0.05).After treatment,the levels of SOD and IL-2 in the observation group were higher than those in the control group,while the levels of MDA,ROS,IL-6,TNF-α,APACHE Ⅱ,and SOFA scores were lower than those in the control group,and the differences were statistically significant(P＜0.05).The incidence of infectious complications(3.17％)was lower than that of the control group(12.70％),and the difference was statistically significant(P＜0.05).CONCLUSION The efficacy of roxatidine combined with pantoprazole in treating SU in critically ill patients is superior to that of pantoprazole alone.The combination could relieve oxidative stress and inflammation of the body,and reduce the occurrence of infection-related complications.
维普
万方数据